Home » Posts tagged 'sopheon'

Tag Archives: sopheon

Ian Pollard – Autotrader Enjoys Strong Growth

Autotrader AUTO The year to the 31st March was one of strong revenue and profit growth, although the second half felt the effects of broader economic uncertainty. Revenue for the year rose by 7% and profit before tax by10%. A final divided of 4p per share is proposed up from last years 3.5p and making a total for the year of 5.9p per share as against last years 5.2p per share. The new year has started well.

Sopheon SPE is full of praise for its recent past performances and it looks like the air will be full of self congratulation at today’s AGM. As for the immediate outlook, positive momentum has continued and full year revenue so far has risen by 34%, an all time high for its mid year AGM report. The Board says it continues to be enthusiastic.

Intercede Group plc IGP Preliminary results for the year to 31st March show a rise of 11% in revenue, after a strong year end. However this made little impression on last years losses of £3.9m. which fell to £3.8m., despite staff numbers being slashed from 120 to 98. A new Chief Executive has been appointed and the management team has been reorganised in an attempt to bring the company back to profitability.

Joules Group plc JOUL updates that for the 52 weeks to the 27th May group revenue rose by 18.5% with retail up by 15.9% and wholesale by 24%. Underlying profit before tax will be marginally ahead of analysts expectations.The strength and appeal of the brand is credited with the success.

Veltyco Group plc VLTY proposes paying a maiden dividend of 0.25p per share for the year to 31st December 2017 after revenue grew by 165% following the completion of acquisitions and operating EBITDA rose by 260%. The momentum has continued into the current year with revenue so far growing by a further 60% compared to 2017.

 

Beachfront villas & houses for sale in Greece;   http://www.hiddengreece.net

Brand CEO Alan Green talks Sopheon #SPE, Feedback #FDBK & STM Group #STM on Vox Markets podcast

Brand CEO Alan Green discusses Sopheon #SPE, Feedback #FDBK & STM Group #STM with Justin Waite on the Vox Markets podcast.  Interview starts at 16 minutes 35 seconds in.

Sopheon #SPE has risen 8X since first being flagged up by VectorVest. We still rate the stock as a buy!

Sopheon partners with customers to provide complete enterprise solutions

There is lots still to come in this excellent growth prospect.

Woking-based Sopheon (SPE.L) is engaged in the provision of software and services in the product lifecycle management (PLM) market. The Company operates in two segments: N America and Europe. Its Accolade solution provides integrated support for innovation planning, roadmapping, idea and concept development, process, project, portfolio, resource and in-market management. Its offerings include alignment of long-term innovation plans with market requirements, industry regulations, and supply chain capabilities; generation and development of ideas and concepts to fill gaps relevant to achieving strategic initiatives; process and project management that tracks and enables decision making, focused on evaluating projects associated with innovation initiatives, and data management, analytics and integrity tools. Subsidiaries include Sopheon Corporation, Alignent Software, Inc., Sopheon NV, Sopheon UK Ltd and Sopheon GmbH.

Examine this trading opportunity and a host of other similar stocks. A single payment of £5.95 gives access to the VectorVest Risk Free 30-day trial. More here

On Monday 29th Jan 2018, SPE updated on trading for the year ended 31 Dec 2017. The strong trading in the closing weeks of the year resulted in two substantial Accolade deals signed, one in the USA and one in Germany, each with a multinational enterprise that is an undisputed leader in its field. Consequently, the board expects that reported revenues for the year will be over $28m, up from $23m in 2016, and comfortably ahead of current market expectations. EBITDA and PTP will also be significantly ahead of current market expectations, with a year-end net cash position expected at $9.5m (2016: $4.2m). Looking forward overall revenue visibility for 2018 already stands at $18m, vs. $13m at this time last year. FY results will be announced on March 22nd 2018.

What VectorVest sees in Sopheon

VectorVest first identified SPE as a quality investment opportunity as far back as 2016 when the stock traded at around 70p. A spectacular 8-fold return since then sees SPE trading at 560p today, but despite this the VectorVest stock analysis and portfolio management system indicates that there is considerably more upside to come. Among a range of metrics highlighting value, the Earnings Growth Rate (GRT), (which reflects a company’s one to three year forecasted earnings growth rate in percent per year) sees SPE score 17%, which VectorVest considers to be very good. The VST-Vector metric (VST) and the master indicator for ranking every stock in the VectorVest database, logs a rating of 1.28, again very good on a scale of 0.00 to 2.00. Finally, despite the meteoric rise in the stock price, the VectorVest Value metric attributes a current value of 646p per share to SPE, meaning the company is still undervalued at the current 560p.

The chart of SPE.L is shown above over the last two years of trading. The green line study above the price reflects the VectorVest valuation while the blue line study shows the growth of Earnings per share (EPS) over the period. The share is on a Buy recomedendation on VectorVest after recently gapping through a 52 week high. This is regarded by technical analysts as a bullish sign. Also of interest to technical analysts is the “pennant” chart pattern from which the share broke on the 4th January 2018. The target from this breakout by conventional charting techniques is approximately 700p.

Can Sopheon keep going up?

Some investors may be put off by investing into SPE at such heady levels given the 8-fold increase in value. But the cash generative nature of this well-managed software business is precisely why it’s stock has historically delivered such strong returns for shareholders to date, and those same qualities exist in abundance at SPE today. VectorVest believes an ‘if it isn’t broke, why try to fix it’ approach is warranted for SPE, with every reason to keep buying the stock for continuing growth.

Dr David Paul

January 31 2018

Readers can examine trading opportunities on SPE and a host of other similar stocks for a single payment of £5.95. This gives access to the VectorVest Risk Free 30-day trial, where members enjoy unlimited access to VectorVest UK & U.S., plus VectorVest University for on-demand strategies and training. Link here to view.

VectorVest Unisearch

On VectorVest a simple search using the Unisearch tool will quickly find shares that are undervalued with good fundamentals that have just issued a Buy recommendation. This will give the active trader a short list of many high probability trading opportunities each week. Traders now have the opportunity to spend five weeks discovering VectorVest’s unique simplicity, automation and independent guidance. Just £5.95 buys a 5 week trial to enable deep exploration, or how the system can assist in smarter trading in as little as 10 minutes a day. Powerful tools. Proven strategies. Unique Perspectives.

Link here for more info and to set up a trial. 

European Financial Publishing Limited T/A VectorVest UK (VectorVest) is authorised and regulated by the Financial Conduct Authority under register number 543038. You should remember that the value of investments and the income derived therefrom may fall as well as rise and you may not get back the amount that you invest. Past performance is not a reliable guide to the future. This material is directed only at persons in the UK and is not an offer or invitation to buy or sell securities. If investors are in any doubt of the suitability of an investment given their individual circumstances, they are recommended to contact an investment manager or independent financial adviser who may be able to provide tailored advice. Opinions expressed whether in general or both on the performance of individual securities and in a wider economic context represent the views of VectorVest at the time of preparation. They are subject to change and should not be interpreted as investment advice. VectorVest and connected companies, clients, directors, employees and other associates, may have a position in any security, or related financial instrument, issued by a company or organisation mentioned on this site. European Financial Publishing Limited is a company incorporated in Scotland under Company Number SC357322 with its registered address at Exchange Tower, 19 Canning Street, Edinburgh EH3 8EH. Email: support@VectorVest.comFREE! For free VectorVest analysis on any stock, go to this link here

Ian Pollard – easy Hotel trading strongly

easy Hotel plc EZH Strong trading experienced in the previous year has continued through the year to the end of September. The groups owned hotels have significantly outperformed both the competition and the wider OK hotel market. Franchised hotel have also traded strongly especially in continental Europe.In 2018 four new owned hotels will be opened adding a total of 517 rooms, whilst new franchised hotels due to be opened will add a further 798 rooms.

Sopheon plc SPE The board now expects revenue for the year to he 31st December will be comfortably ahead of market expectations whilst EBITDA and pre tax profits should be significantly ahead.This follows two substantial deals in the final quarter leading to an increase from 49 to 59 in licences for the year as a whole.

James Halstead plc JHD Turnover for the half year to the 31st December rose by 5% to record levels after strong December trading in the UK, Germany and Australia

 

Utilitywise UTW Trading in the company’s shares will be temporarily suspended at 7-30 this morning as it will not be able to publish its annual audited accounts by the end of this month. The delay is due to the amount of work involved in its new revenue recognition policy and the suspension will be lifted as soon as it is able to publish its results.

Telit Communications TCM has received expressions of interest from numerous parties with regard to the proposed sale of its automotive division and due diligence is now being undertaken. There is no intention of selling any other divisions or activities.

Defenx DFX confirms that revenues for the year to 31st December will be materially below those of the previous year resulting a significant loss for 2017. The appointment of a new CEO in November has resulted in progress being made in solving the company’s problems but difficulties remain in collecting in trade debts and collections have been limited during the last three months.

Beachfront villas & houses for sale in Greece;   http://www.hiddengreece.net

Ian Pollard – Tiddlers Taking Off

Taptica TAP Tremor Video has performed better than expected and has achieved profitability during 2017 rather than 2018. With significant contributions to revenue from its newly opened international offices, it now expects to report adjusted EBITDA for full year 2017 will be ahead of market expectations.

Sopheon plc SPE The build up of momentum highlighted in the interim results in August has continued, particularly in the fourth quarter. Inidications now are that revenues, EBITDA and pre tax profits for the year to the end of December will all exceed market expectations.

Symphony Environmental Technologies SYM expects profit before tax for the year to 31st December will be significantly  higher than current market expectations. Revenue has risen to £8.2m from last years £6.8m and profits before tax it is anticipated will more than triple, from last years £123,000 to at least £400,000 for the current year. 2018 is looked forward to with optimism.

Churchill China CHH expects that its operating performance for the year to the 31st December will slightly ahead of current market estimates, following good revenue growth in export markets.

Find beachfront villas & houses for sale in Greece;   http://www.hiddengreece.net

David Paul of VectorVest talks TAP, SOP, MIDW & GFM on Core Finance TV

VectorVest MD, Dr David Paul presents the stock picks for the week – Taptica (TAP), Sopheon (SOPH), Midwich Group (MIDW) and Griffin Mining (GFM) on Core Finance TV.

Dr David Paul, MD of VectorVest discusses Sopheon (SPE), Triad Group (TRD), Defenx (DFX) & Morgan Sindall (MGNS) on TipTV

Dr. David Paul, MD at Vector Vest talks about VectorVest Edge Strategy, which involves screening shares for favourable technical and fundamental factors and buying them when the overall market is rising. Stocks discussed today include Sopheon (SPE), Triad Group (TRD), Defenx (DFX), Morgan Sindall (MGNS).

Brand CEO Alan Green talks Andalas Energy (ADL), Sopheon (SPE), Watchstone Grp (WTG) & Advanced Oncotherapy (AVO) on Vox Markets podcast

Brand CEO Alan Green discusses Andalas Energy (ADL), Sopheon (SPE), Watchstone Grp (WTG) & Advanced Oncotherapy (AVO) with Justin Waite on the Vox Markets podcast. The interview is 17 minutes 45 seconds in.

Sopheon (SPE) – Still undervalued says VectorVest due to forecasted earnings growth

VVUKlogoUK based Sopheon plc (SPE) is engaged in the provision of software and services in the product lifecycle management (PLM) market. The Company operates in two segments: North America and Europe. It’s Accolade solution consists of various modules, including Portfolio Management, which enable companies to prioritize product ideas, focus on resources, and bring the right products to market on time; Idea Development that develops new product ideas; Resource Planning, which aligns resources with new product development opportunities; document routing software; and Microsoft Integration that ensures process adoption and adherence. The company also offers Vision Strategist, a strategic product planning solution designed for product and IT road mapping; Accolade for Clinical Trials, which structures and automates the clinical trial process; Accolade healthcare protocol management software; and Evidence Monitor solution, which monitors targeted medical journals and databases, filters and analyzes their content, and provides alerts on information and developments related to the user’s areas of specialization. In addition, it provides consultancy and implementation services, such as requirements definition, configuration, installation, and post-production support. It principally serves automotive, aerospace, and defense sectors.Its subsidiaries include Sopheon Corporation, Alignent Software, Inc., Sopheon NV, Sopheon UK Ltd and Sopheon GmbH.

On 25th August 2016, Sopheon published interim results to the end of June, revealing a pre-tax profit of $1.6m compared to a $0.5m loss previously, on revenues up to $11.5m from $8.4m. EBITDA improved to $2.9m ($0.9m). Sopheon said 20 license transactions were closed in the period from new and existing customers compared to 15 in 2015. This included “a very substantial” order from an existing enterprise tier customer, meaning that although license deal volume increased by a third, license revenues doubled. Additionally, services revenues increased by over 50%. Looking forward, Sopheon said revenue visibility for the full-year 2016 now stands at $18.4m from just under $17m at the time of the annual general meeting in June and $15m in the previous year. Chairman Barry Mence said: “We believe that Sopheon is well positioned to capitalise on the opportunities and deliver continued progress.”

The growth potential at Sopheon had been picked up by the VectorVest stock screening system at the start of the year, when the stock traded at around 70p. Among a range of metrics highlighting value, the stock was flagged on the VectorVest Growth to P/E Ratio (GPE), which compares earnings growth rate to P/E ratio. It was noted that Sopheon has a GPE rating of 3.69. With long-term interest rates currently at 3.79%, the operative GPE ratio is 0.14, meaning Sopheon is considered to be undervalued. Secondly the Earnings Growth Rate (GRT), (which reflects a company’s one to three year forecasted earnings growth rate in percent per year) sees Sopheon score very highly with a GRT of 38%. Finally, despite the recent rise in the stock price, the VectorVest Value metric attributes a current value of 525.06p per share to Sopheon, meaning the company is still undervalued at the current 286.00p per share.

SPE-logo

The chart of Sopheon is shown. The green line above the price chart is the VectorVest calculated valuation while the blue line in the window below the price is Earnings per Share (EPS). Technically the share is charting a symmetrical triangle with the price currently at support within the triangle. If the triangle breaks to the upside (and the fundamentals strongly think it should) then the target can be calculated by measuring the height of the move prior to the consolidation. This is known as a measured move by chartists and it suggests that a move of 200p is probable. This would take the share price to the current valuation of 525p. Traders can buy at support within the triangle or wait for a breakout of the trendline defining resistance within the triangle. VectorVest automatically calculates a stop loss and at the moment this should be placed at around 260p.

To summarise, the rate at which Sopheon continues to grow earnings marks this company out as a quality play. VectorVest attributes a current value of 525.06p per share to the stock, meaning the company is still undervalued at the current 286.00p per share. Buy.

David Paul

October 24th 2016

PS: Readers can examine the opportunity at Sopheon, and indeed on a host of other similar stocks for a single payment of £5.95. This gives access to the VectorVest Risk Free 5-week trial, where members enjoy unlimited access to VectorVest UK & U.S., plus VectorVest University for on-demand strategies and training. Link here to view.

FREE! For free VectorVest analysis on any stock, go to this link here

VectorVest Unisearch

On VectorVest a simple search using the Unisearch tool will quickly find shares that are undervalued with good fundamentals that have just issued a Buy recommendation. This will give the active trader a short list of many high probability trading opportunities each week. Traders now have the opportunity to spend five weeks discovering VectorVest’s unique simplicity, automation and independent guidance. Just £5.95 buys a 5 week trial to enable deep exploration, or how the system can assist in smarter trading in as little as 10 minutes a day. Powerful tools. Proven strategies. Unique Perspectives.

Link here for more info and to set up a trial. 

European Financial Publishing Limited T/A VectorVest UK (VectorVest) is authorised and regulated by the Financial Conduct Authority under register number 543038. You should remember that the value of investments and the income derived therefrom may fall as well as rise and you may not get back the amount that you invest. Past performance is not a reliable guide to the future. This material is directed only at persons in the UK and is not an offer or invitation to buy or sell securities. If investors are in any doubt of the suitability of an investment given their individual circumstances, they are recommended to contact an investment manager or independent financial adviser who may be able to provide tailored advice. Opinions expressed whether in general or both on the performance of individual securities and in a wider economic context represent the views of VectorVest at the time of preparation. They are subject to change and should not be interpreted as investment advice. VectorVest and connected companies, clients, directors, employees and other associates, may have a position in any security, or related financial instrument, issued by a company or organisation mentioned on this site. European Financial Publishing Limited is a company incorporated in Scotland under Company Number SC357322 with its registered address at Exchange Tower, 19 Canning Street, Edinburgh EH3 8EH. Email: support@VectorVest.com

Daily Actions – UK Main & AIM markets 24032016

IntellisysLogoDaily Actions is a daily summary analysis of changes in short term actions from our Daily Recs – AIM and Daily Recs Main markets reports. This report is typically distributed before the open of trading in London

AIM Market

ST Rec. changed
From To
Basic Resources    
Ariana Resources Neutral Buy
Tertiary Minerals Buy Neutral
Zincox Resources Neutral Buy
Financial Services    
Advanced Oncotherapy Buy Neutral
Health Care    
Sareum Holdings Neutral Buy
Industrial Good & Services    
Dart Group Neutral Sell
LPA Group Neutral Sell
Tricorn Group Sell Neutral
Oil & Gas – Explorers    
Petrel Resources Neutral Buy
Technology    
Brady Sell Neutral
Sopheon Neutral Buy

Main Market

ST Rec. changed
From To
Aerospace & Defence
Cobham Buy Neutral
Banks    
HSBC Buy Neutral
Royal Bank of Scotland Neutral Buy
Chemicals    
Synthomer Neutral Sell
House Construction    
Persimmon Neutral Sell
General Retail    
Kingfisher Neutral Sell
Media & Entertainment    
Johnston Press Neutral Buy
Trinity Mirror Neutral Buy
WPP Neutral Sell
Mining    
Randgold Resources Neutral Sell
Support Services    
Rentokil Initial Neutral Sell

 

 

RISK WARNING

Intellisys Intelligent Analysis Limited (‘Intellisys’) does not make personal recommendations. The information in this publication is provided solely to enable you to make your own investment decisions. If you are unsure about dealing in shares and other equity investments, you must contact your financial adviser as these types of investments may not be suitable for everyone. The value of stocks and shares, and the income from them, can fall as well as rise and you may not get back the full amount you originally invested. If denominated in a foreign currency, fluctuations in the exchange rate will also affect the value of stocks and shares and the income from them. Past performance is not necessarily a guide to future performance. You agree to abide fully with Intellisys’ Term & Conditions, which are available to www.intellisys.uk.com

 

The full reports are available from Intellisys Intelligent Analysis website (www.intellisys.uk.com) by clicking on the ‘Research’ tab.

 

 

DISCLAIMER: Intellisys Intelligent Analysis Limited has prepared this report. Intellisys (“Intellisys”) is the trading name of Intellisys Intelligent Analysis Limited. Intellisys Intelligent Analysis Limited is a provider of financial research reports that indicate the possible value of quoted company shares. The information contained within any and all of Intellisys’ reports are designed to present an objective assessment of the possible value or relative value of a company and/or an actuarial sector or stock market index. Intellisys utilises as extensive as possible range of valuation tools and proprietary systems to derive its outputs. The base data for the models are derived from sources believed to be accurate but Intellisys Intelligent Analysis Limited does not warrant or guarantee the accuracy or reliability of the source data or its models and proprietary systems. Subscribers, and casual readers, should not rely upon the Intellisys’ research outputs when forming specific investment decisions but should seek advice specific to their situation and investment requirements from a person authorised under the Financial Services and Markets Act 2000, before entering into any investment agreement.

Intellisys Intelligent Analysis Limited has used reasonable care and skill in compiling the content of this report. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness or accuracy of the information and no responsibility or liability is accepted to the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. In no event will Intellisys Intelligent Analysis Limited, Intellisys or any of its officers, employees or agents be liable to any other party for any direct, indirect, special or other consequential damages arising from the use of this report.

The Intellisys Intelligent Analysis Limited and/or Intellisys reports are not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the publication or availability of the Intellisys Intelligent Analysis Limited and/or Intellisys information may be prohibited. Persons in respect of whom such prohibitions apply must not access the Intellisys Intelligent Analysis Limited and/or Intellisys reports. Neither this document, nor any copy in whatever form of media, may be taken or transmitted into the United States, Canada, Australia, Ireland, South Africa or Japan or into any jurisdiction where it would be unlawful to do so. Any failure to comply with this restriction may constitute a violation of relevant local securities laws. Recipients of Intellisys Intelligent Analysis Limited and/or Intellisys reports outside the UK are not covered by the rules and regulations made for the protection of investors in the UK.

Any user distributing information taken from any Intellisys Intelligent Analysis Limited or Intellisys report and/or the Intellisys website, in whatever form, to any other person, agrees to attach a copy of this Disclaimer and the Terms and Conditions of Use pages and obtain the agreement of such other person to comply with the terms set forth.

Intellisys’ published reports are published for information purposes and only available to market counterparties, high net-worth and sophisticated individual investors.

No Intellisys report constitutes an offer or invitation to trade, sell, purchase or acquire any shares or other financial instruments in any company or any interest therein, nor shall it form the basis of any contract entered into for the sale of shares or any other financial instrument in any company.

Intellisys Intelligent Analysis Limited believes that the information within each and any of its reports to be correct, but its accuracy or completeness cannot be guaranteed. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or mis-statements, negligent or otherwise.

Intellisys Intelligent Analysis Limited (including its Directors, employees and representatives) or a connected person may have positions in or options or other financial instruments on any of the securities mentioned within a report, and may buy, sell or offer to purchase or sell such securities from time to time, subject to restrictions imposed by internal rules.

Subscribers, and casual reader, are reminded that the value of any financial instrument may go up or down and that past performance is not necessarily a guide to future performance.

Intellisys Intelligent Analysis Limited is not registered with or regulated by any financial regulatory authority and does not offer, provide or purport to provide or offer investment advice. Intellisys Intelligent Analysis Limited can be contacted at Woodfield Cottage, The Street, Mortimer, Berkshire, United Kingdom RG7 3DW.

 

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.